However, through further explorations of HAI-1/HGF signaling and its roles in reshaping local immune responses, it may be possible to substantiate HAI-1 loss as a biomarker for such an approach, thereby identifying additional NSCLC patients who would derive clinical benefit from such combination strategies. This evidence concerns the gene HGF and non-small cell lung carcinoma.